Kathmere Capital Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Kathmere Capital Management LLC increased its stake in Gilead Sciences by 14.4%, owning a total of 24,979 shares valued at approximately $2.77 million as of the end of Q2.
• Gilead's recent earnings report showed an EPS of $2.01, surpassing expectations, with quarterly revenue reaching $7.08 billion, which is a 1.4% increase year-over-year.
• The company declared a quarterly dividend of $0.79 per share to be paid on September 29, yielding 2.8% annually, with a payout ratio of 62.95%.

Kathmere Capital Management LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,979 shares of the biopharmaceutical company's stock after purchasing an additional 3,149 shares during the quarter. Kathmere Capital Management LLC's holdings in Gilead Sciences were worth $2,769,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in GILD. Price T Rowe Associates Inc. MD increased its holdings in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. Nuveen LLC bought a new position in shares of Gilead Sciences in the first quarter worth $620,415,000. GAMMA Investing LLC increased its holdings in shares of Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after purchasing an additional 2,532,070 shares during the period. Kingstone Capital Partners Texas LLC bought a new position in shares of Gilead Sciences in the second quarter worth $238,083,000. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock worth $282,706,000 after purchasing an additional 2,040,261 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Up 1.0%

Shares of NASDAQ:GILD opened at $112.10 on Friday. The stock's 50-day moving average price is $114.41 and its 200-day moving average price is $109.95. Gilead Sciences, Inc. has a 12-month low of $82.82 and a 12-month high of $121.83. The stock has a market capitalization of $139.09 billion, a P/E ratio of 22.33, a price-to-earnings-growth ratio of 0.75 and a beta of 0.36. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same period last year, the firm earned $2.01 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, UBS Group increased their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $117.17.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,390,030 over the last three months. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.